KaydedilenlerDerginizi ekleyin

Dergiler / Retina-Vitreus / 2018 / Cilt: 27 - Sayı: 2

Effects of Tadalafi l on Macular Parameters and Choroidal Thickness in Diabetic Patients

Diyabetik Hastalarda Tadalafi lin Koroid Kalınlığı ve Makula Parametreleri Üzerine Etkileri

Murat Atabey ÖZER
Serkan ÖZEN
NİHAT POLAT
ERCAN ÖĞREDEN
ERHAN DEMİRELLİ
ALİ BEYTUR
Yaşar KÜÇÜKSÜMER
Sayfa
148–153
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The long-term use of systemic tadalafi l does not cause any adverse effects on the retina and the macula in diabetic patients with ED.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To investigate the effects of tadalafi l on macular parameters and choroidal thickness in diabetic patients with erectile dysfunction (ED).
📊
Temel Bulgular & Veri:Materials and methods: Total 37 diabetic patients with ED were included in this single-centred, open-label prospective study.
💡
Sonuç & Katkı:The long-term use of systemic tadalafi l does not cause any adverse effects on the retina and the macula in diabetic patients with ED.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: To investigate the effects of tadalafi l on macular parameters and choroidal thickness in diabetic patients with erectile dysfunction (ED). Materials and methods: Total 37 diabetic patients with ED were included in this single-centred, open-label prospective study. The treatment was initiated with 5 mg tadalafi l hydrochloride daily for 3 months. Choroidal thickness, central macular thickness (CMT), and total macular volume (TMV) measurements were performed using spectral domain optical coherence tomography (SD-OCT). SD-OCT and visual acuity (VA) measurements were repeated during all visits. Fundus fl uorescein angiography (FFA) was also performed at baseline and at the 12 th week. Results: There was a statistically signifi cant increase in the choroidal thickness compared to that at baseline at all visits except at the fi rst visit (mean central foveal choroidal thickness, baseline; 248.7 ± 21.5, 1 st day; 247.4 ± 23.2, 4 th week; 275.9 ± 21.3, and 12 th week; 275.1 ± 24.4, μm, p 0.05). Conclusions: Choroidal thickness safely increases in response to systemic tadalafi l administration. The long-term use of systemic tadalafi l does not cause any adverse effects on the retina and the macula in diabetic patients with ED.

Abstract

Amaç: Erektil disfonksiyonlu(ED) diyabetik hastalarda tadalafi lin koroid kalınlığı ve maküla parametreleri üzerine etkilerini araştırmak. Materyal ve Metod: Bu tek merkezli açık etiketli prospektif çalışmaya ED tanılı diyabetik 37 hasta dahil edildi. Bu hastalara 3 ay boyunca günlük 5 mg Tadalafi l hidroklorür başlandı. Koroidal kalınlık, santral makuler kalınlık(SMK) ve total makuler volüm(TMV) spectral optik kohorens tomografi (SD-OKT) kullanılarak değerlendirildi. tüm vizitlerde tekrarlandı. Tüm kontrollerde SD-OKT ve görme keskinliği(GK) ölçümleri tekrarlandı. Ayrıca başlangıçta ve 12. haftada tüm hastalara fundus fl oresein anjiografi (FFA) uygulandı. Sonuçlar: İlk visit hariç diğer tüm kontrollerde başlangıca gore koroid kalınlığında istatistiksel olarak anlamlı düzeyde artış olduğu görüldü(ortalama santral foveal koroidal kalınlık, başlangıç; 248.7 ± 21.5, 1. gün; 247.4 ± 23.2, 4. hafta; 275.9 ± 21.3, ve 12. hafta; 275.1 ± 24.4, μm, p 0.05). Tartışma: Uzun süreli, düşük doz sistemik tadalafi l kullanımı diyabetik hastalarda güvenli bir şekilde koroid kalınlığını artırmaktadır. Ayrıca retina ve maküla üzerinde yan etkiye sebep olmamaktadır.

🔖

Bu Makaleye Atıf Yap

ÖZER, M. A., ÖZEN, S., POLAT, N., ÖĞREDEN, E., DEMİRELLİ, E., BEYTUR, A., KÜÇÜKSÜMER, Y. (2018). Effects of Tadalafi l on Macular Parameters and Choroidal Thickness in Diabetic Patients. Retina-Vitreus, Cilt: 27 - Sayı: 2, 148–153. https://ajindex.com/articles/304852

Kaynakça (10)

  1. Akkus E, Kadioglu A, Esen A, Doran S, Ergen A, Anafarta K et al. Prevalence and correlates of erectile dysfunction in Turkey: a population-based study. Eur Urol 2002; 41:298-304.
  2. Ventimiglia E, Capogrosso P, Montorsi F, Salonia A. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf. 2016;15(2):141-52.
  3. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T; Vardenafi l Diabetes Study Group. Vardenafi l, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes. Diabetes Care. 2003;26(3):777-83.
  4. Pires I, Santos AR, Nunes S, Lobo C. Macular thickness measured by stratus optical coherence tomography in patients with diabetes type 2 and mild nonproliferative retinopathy without clinical evidence of macular edema. Ophthalmologica. 2013;229(4):181– 6. Demir M, Oba E, Dirim B, Ozdal E, Can E. Central macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy. BMC Ophthalmol. 2013;13:11. van Dijk HW, Kok PH, Garvin M, Sonka M, Devries JH, Michels RP, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(7):3404–9.
  5. Cabrera DeBuc D, Somfai GM. Early detection of retinal thickness changes in diabetes using Optical Coherence Tomography. Med Sci Monit. 2010;16(3):15–21.
  6. Sim DA, Keane PA, Fung S, Karampelas M, Sadda SR, Fruttiger M, et al. Quantitative analysis of diabetic macular ischemia using optical coherence tomography. Invest Ophthalmol Vis Sci. 2014; 21;55(1):417-23.
  7. Kim DY, Silverman RH, Paul Chan RV, Khanifar AA, Rondeau M, Lloyd H, et al. Measurement of Choroidal Perfusion and Thickness Following Systemic Sildenafi l (Viagra®). Acta Ophthalmol. 2013; 91(2): 183–188.
  8. McCulley TJ, Luu JK, Marmor MF, Feuer WJ. Effects of sildenafi l citrate (Viagra) on choroidal congestion. Ophthalmologica 2002; 216: 455–8. Hayreh SS. Effect of sildenafi l citrate (viagra) on the ocular circulation. Am J Ophthalmol 2002; 133: 169–70.
  9. Dundar SO, Dayanir Y, Topaloğlu A, Dundar M, Kocak A. Effect of sildenafi l on ocular hemodynamics in 3 months regular use. Int J Impot Res 2006; 18: 282–6.
  10. Boltz A, Luksch A, Wimpissinger B, Maar N, Weigert G, Frantal S, et al. Choroidal blood fl ow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010; 51(8):4220–5.